- 1 Antibiotic Utilisation Patterns in Tanzania: A Retrospective Longitudinal Study
- 2 Comparing Pre- and Post-COVID-19 Pandemic Using Tanzania Medicines and Medical
- 3 Devices Authority Data
- 4 Raphael Z. Sangeda<sup>1</sup>, Sahani M. William<sup>1</sup>, Faustine Cassian Masatu<sup>2</sup>, Adonis Bitegeko<sup>2</sup>,
- 5 Yonah Hebron Mwalwisi<sup>2</sup>, Emmanuel Alphonse Nkiligi<sup>2</sup>, Pius Gerald Horumpende<sup>3,4,5</sup>,
- 6 Adam M. Fimbo<sup>2</sup>
- <sup>1</sup>Department of Pharmaceutical Microbiology, Muhimbili University of Health and Allied
- 8 Sciences, PO Box 65013, Dar es Salaam, Tanzania
- <sup>2</sup>Tanzania Medicines and Medical Devices Authority, PO Box 1253, Dodoma, Tanzania
- <sup>3</sup>Department of Curative Services, Ministry of Health, P.O. Box 743 Dodoma, Tanzania.
- 11 College, Moshi, Tanzania
- <sup>4</sup>Kilimanjaro Clinical Research Institute (KCRI), Moshi, Tanzania
- <sup>5</sup>Lugalo Infectious Diseases Research Centre, General Military Hospital (GMH) and Military
- 14 College of Medical Sciences (MCMS), P.O. Box 4000 Dar es Salaam, Tanzania
- \*Correspondence to Raphael Zozimus Sangeda email: <a href="mailto:sangeda@gmail.com">sangeda@gmail.com</a>
- 18 Short title: Influence of COVID-19 on Antibiotic Utilization Patterns in Tanzania
- 19 **Synopsis**

15

- 20 Background: Antimicrobial resistance (AMR) is a growing public health concern globally, and
- 21 misuse of antibiotics is a major contributor.
- 22 Objective: This study investigated antibiotic utilisation patterns before and after the COVID-19
- 23 pandemic in Tanzania using data from the Tanzania Medicines and Medical Devices Authority
- 24 (TMDA).

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

Methods: This retrospective longitudinal study analysed secondary data. The study compared antibiotics consumption in defined daily doses (DDD) per 1000 inhabitants per day (DID) in two distinct eras: 2018-2019 as the pre-COVID-19 era and 2020-2021 as the post-COVID-19 era. Data was reorganised using Microsoft Power BI, and statistical analysis was conducted using SPSS software. Results: The study analysed 10,614 records and found an overall increase in antibiotics consumption from 2018 to 2021. When we divided the consumption of antibiotics into a pre- and post-COVID time period, with the pre-COVID period being 2018 and 2019 and the post-COVID period being 2020 and 2021, we found that the consumption was 61.24 DID in the post-COVID era and 50.32 DID in the pre-COVID era. Levofloxacin had the highest percentage increase in use, with a 700% increase in DID after the pandemic. Azithromycin had a 163.79% increase, while cefotaxime had a 600% increase. In contrast, some antibiotics exhibited a decrease in usage after the pandemic, such as nalidixic acid, which had a 100% decrease, and cefpodoxime, 66.67% decrease. Conclusion: The increase in antibiotic consumption during the COVID-19 pandemic highlights the importance of implementing effective antimicrobial stewardship strategies to prevent AMR, especially during pandemics. Introduction Antimicrobial resistance (AMR) poses a serious global health threat by hindering the treatment of bacterial infections. In low and middle-income countries (LMICs), Tanzania included, the misuse and overuse of antibiotics have resulted in high rates of AMR, making it challenging to

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

treat bacterial infections<sup>2,3</sup>. Proper regulation and minimal consumption of antibiotics are crucial in reducing the prevalence of AMR in LMICs<sup>2</sup>. To increase healthcare professionals' capacity for health safety and security and provide awareness on the appropriate use of antibiotics to reduce the development of AMR, global partnerships such as the Global Health Security Agenda (GHSA) and Antimicrobial Stewardship Programs (ASP) have been created. However, the COVID-19 pandemic has led to increased use of antibiotics due to the absence of antiviral therapies, which may contribute to further development of AMR. The second reason for increased antibiotics use has been the lack of proper infection prevention control (IPC) measures in public areas and hospitals.<sup>4</sup> The government of Tanzania has implemented various programs to provide affordable healthcare services to the population, including a pre-payment system and health insurance scheme. Further, the Parliament of Tanzania has recently passed a bill for universal health insurance, awaiting the President's signature into law. However, achieving universal health coverage in Tanzania remains challenging as many citizens still lack access to proper healthcare services and have access to antibiotics without a prescription.<sup>5</sup> The World Health Organization (WHO) has promulgated several guidelines for countries embarking on AMS to optimise antibiotics prescription and dispensing. One such guideline is using the AWaRe (Access, Watch, Reserve) classification of antibiotics in reporting AMU data. According to this AWaRe classification, the Access group consists of antibiotics with activity against a wide range of commonly encountered susceptible bacteria with lower resistance potential than antibiotics in the other groups. The Watch class consists of antibiotics with higher resistance potential and includes most of the highest priority agents among the critically important antimicrobials for human use. The Reserve group includes antibiotics and

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

antibiotic classes that should be reserved to treat confirmed or suspected infections due to multidrug-resistant organisms. Reserve group antibiotics should be treated as "last resort" options. 7,8 This classification emphasises using the reserve group sparingly to preserve strong antibiotics for serious infections. Other guidelines include the Anatomical Therapeutic Chemical (ATC) classification system and the daily defined dose (DDD) system to allow for international standardisation in AMU studies and permit comparison across geographical regions.<sup>9</sup> At the onset of the COVID-19 outbreak in Tanzania in March 2020<sup>10,11</sup> clinicians began administering antibiotics to patients presenting with clinical signs such as cough, fever, and radiological infiltrate indicative of bacterial community-acquired pneumonia. The absence of antiviral therapies with proven efficacy also contributed to the widespread and excessive prescription of antibiotics, leading to increased antimicrobial resistance during the pandemic 11-13. Implementing proper antibiotic stewardship programs and increasing awareness of the appropriate use of antibiotics among healthcare professionals and the general public is pivotal in combating AMR. Collaboration among stakeholders is necessary to ensure effective treatment of bacterial infections to combat AMR.<sup>14</sup> In Tanzania, AMS efforts underpinned in the National Action Plan (NAP) were launched in the National Action Plan (NAP) were la 2017 and the second version<sup>17</sup> in 2022 to help combat AMR. In 2020, the emergence of the COVID-19 pandemic impacted many aspects of life, including antimicrobial use (AMU) in Tanzania and globally. However, there is a paucity of AMU data in Tanzania comparing pre and post-COVID-19 eras to guide AMS. The Tanzania Medicines and Medical Devices Authority (TMDA) regulates the use of antibiotics in the country and collects data on their utilization<sup>15</sup>. TMDA's data on antibiotics utilisation can provide valuable information to develop effective strategies to combat AMR in Tanzania. Therefore, this study aimed to investigate the change in

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

antibiotic utilisation patterns before and after the COVID-19 pandemic in Tanzania, using TMDA data from 2018 to 2021 to determine the trends of use before and during the COVID-19 pandemic outbreak in Tanzania. Methods Study design This retrospective and longitudinal study used data from the Tanzania Medicines and Medical Devices Authority (TMDA), covering four years from 2018 to 2021. Study area The study was conducted in Tanzania Mainland, and the data were collected from TMDA headquarters in Dodoma. The TMDA compiled all importation data at different ports of entry from January 2018 to December 2021, which were included in this study. **Inclusion criteria** The study included all records of antibiotics for intended human use administered systemically. **Exclusion criteria** Antifungals, antivirals, antiparasitic and topical antibiotics and non-antibiotics were excluded from the study. **Data collection** Data were obtained from the TMDA headquarters in Dodoma, where individual importation data were recorded from January 2018 to December 2021. The data collected include product descriptions, generic and trade names, strengths, dosage forms, pack sizes, price, quantities, unit prices, import permits identification, issue dates, supplier names, countries, and local importers.

The TMDA is the National Medicines Regulatory Authority (NMRA) responsible for regulating the importation of medicines into the Tanzanian mainland market. The TMDA has developed and issued regulations and procedures that compel importers to apply for an importation permit. Importers' applications are evaluated, and import permits are issued and archived in the Regulatory Information Management System (RIMS), from which the records of imported medicines can be retrieved <sup>15</sup>. The data included antibiotic generic name, country of origin, ATC class, imports, and WHO AWaRe classification status of antibiotics received. The WHO ATC classification system categorised antibiotics into their respective classes.

Results were expressed using the Daily Defined Doses (DDD) measurement units. Utilisation was expressed in DDD per 1000 inhabitants per day (DID) in accordance with the ATC/DDD

WHO collaborating Center for Statistics Methodology <sup>18</sup>.

### Data analysis

Data collected were checked for completeness, accuracy, and omissions using Microsoft Power BI. Homogeneous data were clustered and coded for easy analysis, and the findings were presented in tables and graphs. Statistical analysis such as paired samples t-test was conducted in Statistical Package for the Social Sciences (SPSS) version 26.0 to assess the impact of the preand post-COVID-19 pandemic on antibiotics consumption in Tanzania. Time series and regression analyses were performed to predict the annual trend of antibiotic utilisation. An autoregressive integrated moving average (ARIMA, 0, 1, 0) model was established to predict the trends of antibiotic use. A p-value of less than 0.05 was considered statistically significant.

#### **Ethical considerations**

Ethical clearance was obtained from the Directorate of Research and Publications of the Muhimbili University of Health and Allied Sciences (MUHAS) with reference number DA. 25/111/28/01/2021. The TMDA granted permission to collect and use its accrued data. Data privacy and confidentiality were observed throughout the study. Patient identifying information was not collected since this did not involve direct patient contact; instead, secondary data from the TMDA importation records was used.

### **Results**

A total of 10,627 records were retrieved from the TMDA information management system. Of these, 9,610 were antibiotics imported for systemic use in humans between 2018 and 2021. A total of 1,017 records were excluded because they referred to antibiotics for either topical or veterinary use, as they were non-J (01) level 2 ATC class and 2022 imports. A total of 117.02 DID was utilised in Tanzania between 2018 and 2021 (Table 1), with a mean (standard deviation) of 29.25 (±4.63) DIDs.

Table 1: Annual distribution of DIDs and number of permits of antibiotics imported in

Year	DID	<b>Number of Permits</b>	
2018	30.39831		2,491
2019	22.53625		2,426
2020	30.96806		2,152
2021	33.11989		2,541
Total	117.0225		9,610

Tanzania between 2018 and 2021


The year 2021 had the highest DID at 33.1, 47.0% higher than 2019, with the lowest DID at 22.5. The consumption in 2021 accounted for 28.30% of DIDs. Annual cumulative DID started shooting up in 2020, where cumulative yearly DID reached 83.9 of the total 117.02 for the four years.

Tanzania imports these antibiotics from across continents and Kenya, India, and China were the major sources of antibiotics in the pre- and post-COVID-19 eras. Tanzania and South Africa were sources of antibiotics only during the pandemic era (Figure 1).



Figure 1: Worldwide country frequency of importations pre-and post-COVID-19 pandemic. The size of the bubble signifies the frequency contributed by the respective country.

The oral and parenteral dosage forms contributed 151.18 (96.93%) and 3.33 (3.075%) of the DIDs, respectively (Figure 2). The contribution of individual dosage forms indicates that capsules contributed the most (Supplementary Figure 1) and Supplementary Table 1.



159

160

161

162

163





Figure 2: DID contribution for oral (Panel A) and parenteral (panel B) antibiotics


Overall, the Access group had the highest DDI at 82.9, followed by Watch, other, and Reserve.

Access group accounted for 70.8% (Figure 3) of DDI, while the WHO suggests > 60%. The


increase in the Watch group of antibiotics parallels a general decline in the Access group (Figure

3) and (Supplementary Figure 2).





C D



Overall (2018-2021)

189 190

191

192

193

194

195

196

197

198

199

200

201

Figure 3: DID contribution per WHO AWaRe classification of antibiotics consumption from 2018-2021 (Panel A-D) and overall for four years (panel E)

The consumption of antibiotics was typically dominated by the Watch class (Supplementary Figure 2).

Using a paired samples t-test, the mean (M) and standard deviation (SD) of antibiotics consumption in the pre-COVID period (M = 1.018, SD = 3.311) was significantly different from the post-COVID period (M = 1.232, SD = 3.796), t (51 = -2.513, p-value = 0.015) and paired sample correlation of 0.994 with effect size, as measured by Cohen's d, being 0.312.

Overall, there was a 21% increase in the utilisation of antibiotics post-COVID-19. Azithromycin (J01FA10) increased by 163% during the pandemic (Table 2) and Supplementary Table 2.

Table 2: Percentage changes in consumption during COVID-19 for top 20 consumed antibiotics aggregated per level 5 WHO ATC classification in DID

Antibiotic (ATC Classification level 5)	Pre- COVID	Post- COVID	Total	% change
Sulfamethoxazole + Trimethoprim				J
(J01EE01)	21.90206	24.134214	46.036274	10.2
Amoxicillin (J01CA04)	8.958047	12.109729	21.067776	35.2
Ampicillin + Cloxacillin (J01CR50)	4.957764	6.056899	11.014663	22.2
Ciprofloxacin (J01MA02)	3.320329	3.875245	7.195574	16.7
Metronidazole (J01XD01)	2.550591	3.007772	5.558363	17.9
Azithromycin (J01FA10)	1.163502	3.063967	4.227469	163.3
Phenoxymethyl Penicillin (J01CE02)	1.839013	2.112984	3.951997	14.9
Erythromycin (J01FA01)	1.103971	1.837235	2.941206	66.4
Tinidazole (J01XD02)	0.988315	1.399698	2.388013	41.6
Amoxicillin + Clavulanate (J01CR02)	0.81814	1.280495	2.098635	56.5
Ceftriaxone (J01DD04)	0.912814	1.147269	2.060083	25.7
Cefalexin (J01DB01)	0.956694	0.637602	1.594296	-33.4
Norfloxacin (J01MA06)	0.929865	0.582542	1.512407	-37.4
Ampicillin (J01CA01)	0.737038	0.699213	1.436251	-5.1
Gentamycin (J01GB03)	0.184052	0.560144	0.744196	204.3
Amoxicillin + Flucloxacillin (J01CR50)	0.1963	0.216417	0.412717	10.2
Ciprofloxacin + Tinidazole (J01RA11)	0.219978	0.157204	0.377182	-28.5
Nitrofurantoin (J01XE01)	0.220675	0.152053	0.372728	-31.1
Tetracycline (J01AA07)	0.09207	0.222064	0.314134	141.2
Chloramphenicol (J01BA01)	0.210731	0.074664	0.285395	-64.6

Considering level 3 of the ATC classification, we noted that antibiotics consumption varies by specific categories. Notably, beta-lactam antibacterials and penicillins (J01C) registered a significant 28.32% increase in consumption. A 4.96 DID increase between post-covid and precovid was noted for the beta-lactam antibacterials (Figure 4) and (Supplementary Table 3).





Figure 4: Contribution of each class (level 3 ATC classification) of antibiotics utilised in Tanzania from 2018 to 2021

On the other hand, aminoglycoside antibacterials (J01G) exhibited a remarkable 186.44% increase. In contrast, amphenicols (J01B) experienced a substantial decrease –(63.79%). The class of macrolides, lincosamides and streptogramins (J01F) flagged a remarkable increase of 110.53% in consumption (Supplementary Table 3). In addition, annual trends of antibiotics at class 3 of the ATC classification were observed (Supplementary Table 4). Similar trends are indicated when considering level 4 ATC classification (Supplementary Table 5). It was noted that the level 3 ATC class of sulfonamides and trimethoprim (J01E) comprised 20.62% of all DID utilised, with the highest totals in pre- and post-COVID eras (Supplementary Table 4).

Overall, the consumption did not follow a linear pattern when fitting a linear curve (Figure 5A).

In addition, the autoregressive integrated moving average (ARIMA) (0, 1, 0) model (Figure 5B) predicts a significant increase in utilisation and forecasts the trends of antibiotics up to the period 2027 modelled using the utilisation trend between 2018 and 2021.






Figure 5: A) Linear curve estimation showing trends of total consumed antibiotics over four years from 2018 to 2021 B) ARIMA model prediction of consumption from 2018 through 2027.

The model estimates that by 2022 and 2027, the DID will reach 34.03 and 38.56 DIDs, respectively.

The top 15 importers of these antibiotics contributed to 90.06% of all DIDs, with the Medical Stores Department (MSD) leading by contributing 20.27% (Figure 6) and (Supplementary Table 6).




Figure 6. Top 15 local importers of antibiotics utilised in Tanzania between 2018 and 2021.

240

241

242

243

244

245

Regarding suppliers, the top 15 contributed 70.78% of the DID of antibiotics in Tanzania (Figure 7) and (Supplementary Table 7). The suppliers were from China, India and Kenya, consistent with the map distribution (Figure 1).




Figure 7: Top 15 foreign suppliers of antibiotics utilised in Tanzania between 2018 and 2021.

### **Discussion**

The Global Action Plan for Antimicrobial Resistance aims to address the mounting challenge of increasing antimicrobial resistance (AMR) through the surveillance of antimicrobial use (AMU) and the development of antimicrobial stewardship (AMS) programs. Consequently, in Tanzania, AMS was introduced through the NAP on AMR<sup>16</sup> in 2017 and the second version of NAP<sup>17</sup> 2023-2028 focuses on monitoring AMU in humans and animals. <sup>15</sup>

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

In this study, we observed an annual increase in the total consumption of antibiotics, reaching 117.02 DDI over four years. The consumption was 64.09 DDI in the post-COVID era and 52.93 DDI in the pre-COVID era. Nevertheless, the mean is 29.25 (±4.01) compared to the mean of 22.07 (±48.85) DID in 2010 to 2016 consumption data in Tanzania<sup>15</sup>. A paired samples t-test indicated a significant difference in means 1.018 vs. = 1.232 in pre and post-COVID periods, respectively, with p-value = 0.015 and paired sample correlation of 0.994. This result suggests a statistically significant increase in antibiotics consumption during the pandemic. The effect size, as measured by Cohen's d, was 0.312, suggesting a small but practically significant increase. The high correlation between pre-COVID and post-COVID consumption (r = 0.994) reinforces the reliability of these findings, suggesting that the COVID-19 pandemic had a notable impact on antibiotics consumption in Tanzania. The combined usage of all antibiotics increased by 21.1% from the pre-COVID period to the post-COVID period. An increase was noted for gentamycin (J01GB03) at +204.3%, followed by azithromycin (J01FA10) at +163.3% and tetracycline (J01AA07) at +141.2%. A decrease was observed in chloramphenicol (J01BA01) (-64.6%), norfloxacin (J01MA06) (-37.4%), and nitrofurantoin (J01XE01) (-31.1%). A % increase in azithromycin was noted in other studies in LMICS and HICs. <sup>19</sup> A study in Croatia showed that azithromycin distribution increased from 1.76 in 2017 to 2.01 Days of Therapy (DOTS) units/1000 inhabitant-days in 2017–2020, indicating azithromycin overuse.<sup>20</sup> Other reports during the pandemic showed that azithromycin consumption increased up to 3 times compared to the pre-COVID period. 19-21 Interestingly, the popularity of azithromycin emerged from reports of its antiviral activity and also from early pandemic reports of screening indicating potential activity for SARS-CoV-2 alone or in combination with hydroxychloroquine.<sup>22</sup> Later, several randomised clinical trials

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

(RCTs) suggested that azithromycin does not reduce hospital admissions, respiratory failure, or death when compared to conventional therapy, and therefore, azithromycin should no longer be used to treat COVID-19.23-28 Several studies have revealed a significant increase in resistance to azithromycin in some strains of Neisseria gonorrhoeae. 22,29 Antibiotic resistance against azithromycin also increased in E. coli<sup>30</sup> and Streptococcus pneumoniae.<sup>31</sup> Therefore, continued use of azithromycin should have been limited to infections for which azithromycin is recommended rather than COVID-19. <sup>22</sup> Examining the consumption at level 3 of ATC classification, we noted a remarkable increase during the post-COVID-19 era of beta-lactam antibacterials, which penicillins (J01C) and aminoglycoside antibacterials (J01G) exhibited. At the same time, amphenicals (J01B) experienced a substantial decrease up to -63.79%. The use of macrolides, lincosamides and streptogramins (J01F) also increased remarkably by 110.53%. This finding underscores the specific impact of the pandemic on the consumption of these antibiotics; the major contributor to this increase was azithromycin. The overall consumption of antibiotics increased from 52.935 DID (pre-COVID) to 64.088 DID (post-COVID), with a total change of 21.07%. Overall, the ATC level 3 class of sulfonamides and trimethoprim (J01E) ranked the top consumed group with only 10.19% increase in consumption, suggesting continued reliance on this class of antibiotics during the pandemic. This could be due to their effectiveness against certain infections and wide availability, especially for HIV/AIDS patients. This is usually indicated by the higher contribution of Sulfamethoxazole + Trimethoprim (J01EE01) used in the HIV program.

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

For tetracycline (level 3 class J01A), there was a moderate consumption increase from 0.145 DID (pre-COVID) to 0.251 DID (post-COVID), a 72.96% increase, even though this class ranked lower compared to previous studies in Tanzania where the class was among the top contributors of consumed antibiotics.<sup>15</sup> It is important to note that the percentage change in usage should be taken with caution since it is calculated based on a relatively small difference in values, and the absolute values of DID for each antibiotic may vary significantly. A recent study conducted in Cameroon during the COVID-19 pandemic revealed that antibiotics were highly overused and misused, leading to increased AMR.<sup>32</sup> This study is one of the few conducted in sub-Saharan Africa to estimate antibiotics utilisation at the national level. The data indicate an increase in the consumption of antibiotics during the pandemic, with a mean of 29.25 DIDs utilised in Tanzania between 2018 and 2021. This average was less than that studied between 2010 and 2016 in Tanzania, where the mean was 57.4 DIDs over seven years. The study conducted in Tanzania from 2017 to 2019 also reported a slightly higher average compared to this study.<sup>33</sup> These results highlight the importance of expanding the monitoring of AMU and implementing AMS programs to address the issue of AMR, especially during global health crises such as the COVID-19 pandemic. The observed changes in antibiotic consumption highlight the need for continued monitoring and the development of interventions to ensure the rational use of antibiotics since the increase in overall consumption may contribute to AMR. Antibiotic stewardship programs must be emphasised post-COVID in the healthcare landscape. The ARIMA forecasted that antibiotics consumption would increase between 2022 and 2027 to reach 34.03 and 38.56 DIDs, respectively. This value is less than the value predicted with the

data from 2010–2016 which estimated that by 2022, the total of antibiotics consumed would reach 89.60 DIDs. <sup>15</sup> This may reflect the impact of AMS under the NAP implementation. <sup>16,34,35</sup>

#### **Limitations of the study**

This study has some limitations. First, it relies on data from importation records of NMRA, potentially subject to variability and errors, which could impact the accuracy of the results. The data does not account for imported antibiotics that had expired or were re-exported to neighbouring countries. These records also exclude efforts by manufacturers that produced some antibiotics locally during the pandemic. Second, while it explores the association between the pandemic and antibiotic consumption, it does not establish causality, as other unaccounted factors may influence consumption trends. Third, the study's aggregated data may not capture regional variations, which is important for understanding local healthcare practices and policies. Additionally, the analysis's specific timeframe during the pandemic may not account for evolving healthcare practices and AMS interventions, and the study does not delve into the underlying factors driving these trends. Further research is warranted to understand the factors driving these consumption trends and their potential impact on public health. Results need to be interpreted with these limitations in mind.

### Conclusion

This study highlights an increase in the consumption of antibiotics during the COVID-19 pandemic, indicating that the COVID-19 pandemic impacted the rise in antibiotics consumption in Tanzania.

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

Recommendations The surge in AMU post-COVID-19 calls for continuous monitoring and interventions to promote rational use of antibiotics to combat AMR through AMS and ensure long-term effectiveness in managing infectious diseases. In addition, more studies using data from community pharmacies and hospitals are needed for a more accurate representation of patient antibiotic consumption. **Availability of Data and Materials** All data are included in this article. Acknowledgement We thank the Tanzania Medicines and Medical Devices Authority (TMDA) staff for providing the importation data. **Funding** This work did not receive any specific funding. **Transparency declarations** None to declare **Supplementary data** Figures and Tables are available as Supplementary data at JAC-AMR Online. References 1. Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet* 2022; **399**: 629–55. Available at: https://linkinghub.elsevier.com/retrieve/pii/S0140673621027240. 2. Otaigbe II, Elikwu CJ. Drivers of inappropriate antibiotic use in low- and middle-income

- 363 countries. *JAC-Antimicrobial Resist* 2023; **5**. Available at:
- https://academic.oup.com/jacamr/article/doi/10.1093/jacamr/dlad062/7187015.
- 3. Browne AJ, Chipeta MG, Haines-Woodhouse G, et al. Global antibiotic consumption and
- usage in humans, 2000–18: a spatial modelling study. *Lancet Planet Heal* 2021; **5**: e893–904.
- Available at: https://linkinghub.elsevier.com/retrieve/pii/S2542519621002801.
- 4. Powell-Jackson T, King JJC, Makungu C, et al. Infection prevention and control compliance
- in Tanzanian outpatient facilities: a cross-sectional study with implications for the control of
- 370 COVID-19. *Lancet Glob Heal* 2020; **8**: e780–9. Available at:
- https://linkinghub.elsevier.com/retrieve/pii/S2214109X20302229.
- 5. Kigume R, Maluka S. The failure of community-based health insurance schemes in Tanzania:
- opening the black box of the implementation process. *BMC Health Serv Res* 2021; **21**: 646.
- Available at: https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-021-06643-6.
- 6. Zanichelli V, Sharland M, Cappello B, et al. The WHO AWaRe (Access, Watch, Reserve)
- antibiotic book and prevention of antimicrobial resistance. Bull World Health Organ 2023; **101**:
- 377 290–6. Available at:
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042089/pdf/BLT.22.288614.pdf.
- 7. WHO 2021 AWaRe classification. Available at:
- https://www.who.int/publications/i/item/2021-aware-classification. Accessed October 9, 2023.
- 8. WHO. The WHO AWaRe (Access, Watch, Reserve) antibiotic book. Available at:
- https://www.who.int/publications/i/item/9789240062382. Accessed October 9, 2023.
- 9. Hamim H, Sangeda RZ, Bundala M, et al. Utilisation Trends of Antiviral and Antifungal

384 Agents for Human Systemic Use in Tanzania From 2010 to 2017 Using the World Health 385 Organization Collaborating Centre for Drug Statistics Methodology. Front Trop Dis 2021; 2: 30. Available at: https://www.frontiersin.org/articles/10.3389/fitd.2021.723991/full. Accessed 386 November 27, 2021. 387 10. Mugabe PA, Renkamp TM, Rybak C, et al. Governing COVID-19: analysing the effects of 388 389 policy responses on food systems in Tanzania. Agric Food Secur 2022; 11: 47. Available at: 390 https://agricultureandfoodsecurity.biomedcentral.com/articles/10.1186/s40066-022-00383-4. 11. Tarimo CS, Wu J. The first confirmed case of COVID-19 in Tanzania: recommendations 391 392 based on lesson learned from China. Trop Med Health 2020; 48: 25. Available at: https://tropmedhealth.biomedcentral.com/articles/10.1186/s41182-020-00214-x. 393 394 12. Mfinanga SG, Mnyambwa NP, Minja DT, et al. Tanzania's position on the COVID-19 395 pandemic. *Lancet* 2021; **397**: 1542–3. Available at: 396 https://linkinghub.elsevier.com/retrieve/pii/S0140673621006784. 13. Mboya EA, Ndumwa HP, Amani DE, et al. Critical illness at the emergency department of a 397 Tanzanian national hospital in a three-year period 2019–2021. BMC Emerg Med 2023; 23: 86. 398 399 Available at: https://bmcemergmed.biomedcentral.com/articles/10.1186/s12873-023-00858-y. 400 14. Simões AS, Maia MR, Gregório J, et al. Participatory implementation of an antibiotic stewardship programme supported by an innovative surveillance and clinical decision-support 401 402 system. *J Hosp Infect* 2018; **100**: 257–64. Available at: https://linkinghub.elsevier.com/retrieve/pii/S0195670118303992. 403 404 15. Sangeda RZ, Saburi HA, Masatu FC, et al. National Antibiotics Utilisation Trends for 405 Human Use in Tanzania from 2010 to 2016 Inferred from Tanzania Medicines and Medical

- Devices Authority Importation Data. *Antibiotics* 2021; **10**: 1249. Available at:
- 407 https://www.mdpi.com/2079-6382/10/10/1249.


- 408 16. Sangeda RZ, Kibona J, Munishi C, et al. Assessment of Implementation of Antimicrobial
- 409 Resistance Surveillance and Antimicrobial Stewardship Programs in Tanzanian Health Facilities
- 410 a Year After Launch of the National Action Plan. Front Public Heal 2020; 8: 454. Available at:
- https://www.frontiersin.org/article/10.3389/fpubh.2020.00454/full. Accessed August 4, 2020.
- 412 17. World Health Organization. United Republic of Tanzania: Second national action plan on
- antimicrobial resistance 2023-2028. Available at:
- https://www.who.int/publications/m/item/united-republic-of-tanzania-second-national-action-
- plan-on-antimicrobial-resistance. Accessed September 20, 2023.
- 18. Hutchinson JM, Patrick DM, Marra F, et al. Measurement of Antibiotic Consumption: A
- Practical Guide to the Use of the Anatomical Therapeutic Chemical Classification and Defined
- Daily Dose System Methodology in Canada. *Can J Infect Dis* 2004; **15**: 29–35. Available at:
- http://www.hindawi.com/journals/cjidmm/2004/389092/abs/. Accessed August 18, 2017.
- 420 19. Gouin KA, Creasy S, Beckerson M, et al. Trends in Prescribing of Antibiotics and Drugs
- Investigated for Coronavirus Disease 2019 (COVID-19) Treatment in US Nursing Home
- Residents During the COVID-19 Pandemic. Clin Infect Dis 2022; 74: 74–82. Available at:
- https://academic.oup.com/cid/article/74/1/74/6167836.
- 424 20. Bogdanić N, Močibob L, Vidović T, Soldo A, Begovać J. Azithromycin consumption during
- the COVID-19 pandemic in Croatia, 2020 Karunasagar I, ed. *PLoS One* 2022; **17**: e0263437.
- 426 Available at: https://dx.plos.org/10.1371/journal.pone.0263437.
- 21. Stoichitoiu LE, Pinte L, Ceasovschih A, *et al.* In-Hospital Antibiotic Use for COVID-19:

- Facts and Rationales Assessed through a Mixed-Methods Study. *J Clin Med* 2022; **11**: 3194.
- 429 Available at: https://www.mdpi.com/2077-0383/11/11/3194.
- 22. Kournoutou GG, Dinos G. Azithromycin through the Lens of the COVID-19 Treatment.
- 431 *Antibiotics* 2022; **11**: 1063. Available at: https://www.mdpi.com/2079-6382/11/8/1063.
- 23. Oldenburg CE, Pinsky BA, Brogdon J, et al. Effect of Oral Azithromycin vs Placebo on
- 433 COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection. *JAMA* 2021; **326**: 490.
- 434 Available at: https://jamanetwork.com/journals/jama/fullarticle/2782166.
- 435 24. Butler CC, Dorward J, Yu L-M, et al. Azithromycin for community treatment of suspected
- 436 COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a
- randomised, controlled, open-label, adaptive platform trial. *Lancet* 2021; **397**: 1063–74.
- 438 Available at: https://linkinghub.elsevier.com/retrieve/pii/S014067362100461X.
- 439 25. Hinks TSC, Barber VS, Black J, et al. A multi-centre open-label two-arm randomised
- superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study
- protocol for the ATOMIC2 trial. *Trials* 2020; **21**: 718. Available at:
- https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04593-8.
- 26. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with
- 444 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet (London,*
- 445 *England*) 2021; **397**: 1637–45. Available at: http://www.ncbi.nlm.nih.gov/pubmed/33933206.
- 27. Gyselinck I, Janssens W, Verhamme P, Vos R. Rationale for azithromycin in COVID-19: an
- overview of existing evidence. BMJ Open Respir Res 2021; 8: e000806. Available at:
- https://bmjopenrespres.bmj.com/lookup/doi/10.1136/bmjresp-2020-000806.


- 28. Furtado RHM, Berwanger O, Fonseca HA, *et al.* Azithromycin in addition to standard of care
- versus standard of care alone in the treatment of patients admitted to the hospital with severe
- 451 COVID-19 in Brazil (COALITION II): a randomised clinical trial. *Lancet* 2020; **396**: 959–67.
- 452 Available at: https://linkinghub.elsevier.com/retrieve/pii/S0140673620318626.
- 453 29. Belkacem A, Jacquier H, Goubard A, et al. Molecular epidemiology and mechanisms of
- resistance of azithromycin-resistant Neisseria gonorrhoeae isolated in France during 2013–14. *J*
- 455 Antimicrob Chemother 2016; **71**: 2471–8. Available at: https://academic.oup.com/jac/article-
- 456 lookup/doi/10.1093/jac/dkw182.
- 457 30. Gomes C, Ruiz-Roldán L, Mateu J, Ochoa TJ, Ruiz J. Azithromycin resistance levels and
- mechanisms in Escherichia coli. *Sci Rep* 2019; **9**: 6089. Available at:
- 459 https://www.nature.com/articles/s41598-019-42423-3.
- 460 31. Hart JD, Samikwa L, Meleke H, et al. Prevalence of nasopharyngeal Streptococcus
- 461 pneumoniae carriage and resistance to macrolides in the setting of azithromycin mass drug
- administration: analysis from a cluster-randomised controlled trial in Malawi, 2015–17. *The*
- 463 *Lancet Microbe* 2022; **3**: e142–50. Available at:
- https://linkinghub.elsevier.com/retrieve/pii/S2666524721002792.
- 32. Djuikoue CI, Yamdeu Djonkouh W, Epie Bekolo C, et al. Prevalence and Antibiotic
- 466 Resistance Pattern of Streptococcus, Staphylococcus, Neisseria meningitidis and
- 467 Enterobacteriaceae in Two Reference Hospitals of Yaoundé: An Overview before and during
- 468 COVID-19 Pandemic Era. Antibiotics 2023; 12: 929. Available at: https://www.mdpi.com/2079-
- 469 6382/12/5/929.
- 470 33. Mbwasi R, Mapunjo S, Wittenauer R, et al. National Consumption of Antimicrobials in

471 Tanzania  $\square$ : 2017 – 2019. 2020; **11**: 2017–9. 472 34. Frumence G, Mboera LEG, Sindato C, et al. The Governance and Implementation of the National Action Plan on Antimicrobial Resistance in Tanzania: A Qualitative Study. *Antibiotics* 473 2021; **10**: 273. Available at: https://www.mdpi.com/2079-6382/10/3/273. 474 475 35. Nkinda L, Mwakawanga DL, Kibwana UO, et al. Implementation of antibiotic stewardship 476 programmes in paediatric patients in regional referral hospitals in Tanzania: experience from prescribers and dispensers. JAC-Antimicrobial Resist 2022; 4: dlac118. Available at: 477 http://www.ncbi.nlm.nih.gov/pubmed/36439992. 478 479 480

481 **Supplementary Figures and Tables** 482 **Antibiotic Utilisation Patterns in Tanzania: A Retrospective Longitudinal Study** Comparing Pre- and Post-COVID-19 Pandemic Using Tanzania Medicines and Medical 483 **Devices Authority Data** 484 Raphael Z. Sangeda<sup>1</sup>, Sahani M. William<sup>1</sup>, Faustine Cassian Masatu<sup>2</sup>, Adonis Bitegeko<sup>2</sup>, 485 Yonah Hebron Mwalwisi<sup>2</sup>, Emmanuel Alphonse Nkiligi<sup>2</sup>, Pius Gerald Horumpende<sup>3,4,5</sup>, 486 Adam M. Fimbo<sup>2</sup> 487 <sup>1</sup>Department of Pharmaceutical Microbiology, Muhimbili University of Health and Allied 488 Sciences, P.O. Box 65013, Dar es Salaam, Tanzania 489 490 <sup>2</sup>Tanzania Medicines and Medical Devices Authority, P.O. Box 1253, Dodoma, Tanzania <sup>3</sup>Department of Curative Services, Ministry of Health, P.O. Box 743 Dodoma, Tanzania. 491 College, Moshi, Tanzania 492 <sup>4</sup>Kilimanjaro Clinical Research Institute (KCRI), Moshi, Tanzania 493 <sup>5</sup>Lugalo Infectious Diseases Research Centre, General Military Hospital (GMH) and Military 494 College of Medical Sciences (MCMS), P.O. Box 4000 Dar es Salaam, Tanzania 495 496 \*Correspondence to Raphael Zozimus Sangeda email: sangeda@gmail.com 497 498 Short title: Influence of COVID-19 on Antibiotic Utilization Patterns in Tanzania 499



## Supplementary Figure 1: Contribution of antibiotics consumption per dosage and by COVID-19 era



Supplementary Figure 2: Distribution of Defined Daily Dose (DDD per 1000 inhabitants per day (DID)) of antibiotics per the World Health Organization's AWaRe class for antibiotics utilised in Tanzania from 2018 to 2020.

### Supplementary Table 1: Annual contribution of consumption of antibiotics per dosage

### **form**

	Year	% contribution				
Dosage form	2018	2019	2020	2021	All time	
Capsules	52.5	67.2	84.7	80.2	71.1	
Injections	2.3	2.5	3.9	3.4	3.0	
Pessaries				0.0	0.0	
Syrup	2.7	1.6	0.7	0.9	1.5	
Tablets	42.5	28.7	10.8	15.5	24.4	
Total	100.0	100.0	100.0	100.0	100.0	

### Supplementary Table 2: Percentage changes in consumption during COVID-19 for top 20 consumed antibiotics aggregated per level 5 WHO ATC classification in DID

	Pre	DID Post		% Change
Antibiotic (ATC level 5 code)	COVID	COVID	Total	
Sulfamethoxazole + Trimethoprim				
(J01EE01)	21.90206	24.134214	46.036274	10.2
Amoxicillin (J01CA04)	8.958047	12.109729	21.067776	35.2
Ampicillin + Cloxacillin (J01CR50)	4.957764	6.056899	11.014663	22.2
Ciprofloxacin (J01MA02)	3.320329	3.875245	7.195574	16.7
Metronidazole (J01XD01)	2.550591	3.007772	5.558363	17.9
Azithromycin (J01FA10)	1.163502	3.063967	4.227469	163.3
Phenoxymethyl Penicillin (J01CE02)	1.839013	2.112984	3.951997	14.9
Erythromycin (J01FA01)	1.103971	1.837235	2.941206	66.4
Tinidazole (J01XD02)	0.988315	1.399698	2.388013	41.6
Amoxicillin + Clavulanate (J01CR02)	0.81814	1.280495	2.098635	56.5
Ceftriaxone (J01DD04)	0.912814	1.147269	2.060083	25.7

Cefalexin (J01DB01)	0.956694	0.637602	1.594296	-33.4
Norfloxacin (J01MA06)	0.929865	0.582542	1.512407	-37.4
Ampicillin (J01CA01)	0.737038	0.699213	1.436251	-5.1
Gentamycin (J01GB03)	0.184052	0.560144	0.744196	204.3
Amoxicillin + Flucloxacillin (J01CR50)	0.1963	0.216417	0.412717	10.2
Ciprofloxacin + Tinidazole (J01RA11)	0.219978	0.157204	0.377182	-28.5
Nitrofurantoin (J01XE01)	0.220675	0.152053	0.372728	-31.1
Tetracycline (J01AA07)	0.09207	0.222064	0.314134	141.2
Chloramphenicol (J01BA01)	0.210731	0.074664	0.285395	-64.6
Cefixime (J01DD08)	0.089679	0.18745	0.277129	109.0
Clarithromycin (J01FA09)	0.116368	0.116796	0.233164	0.4
Ornidazole (J01XD03)	0.124153	0.053845	0.177998	-56.6
Cefuroxime (J01DC02)	0.073682	0.04626	0.119942	-37.2
Ofloxacin (J01MA01)	0.052129	0.06318	0.115309	21.2
Cefadroxil (J01DB05)	0.041038	0.050992	0.09203	24.3
Levofloxacin (J01MA13)	0.008836	0.082444	0.09128	833.0
Doxycycline (J01AA02)	0.052935	0.028352	0.081287	-46.4
Cefotaxime (J01DD01)	0.005643	0.066155	0.071798	1072.3
Cefpodoxime (J01DD13)	0.02914	0.006786	0.035926	-76.7
Moxifloxacin (J01MA15)	0.015046	0.012868	0.027914	-14.5
Dexamethasone + Neomycin + Polymyxin B				
(J01GB05)	0.014225	0.008568	0.022793	-39.8
Lomefloxacin (J01MA07)	0.010553	0.008616	0.019169	-18.4
Meropenem (J01DH02)	0.00761	0.009849	0.017459	29.4
Ampicillin + enzyme inhibitor (J01CA51)	0.011029	0.004753	0.015782	-56.9
Nalidixic Acid (J01MB02)	0.008157		0.008157	-100.0
Lignocaine + Chloramphenicol +				
Beclomethasone Dipropiote + Clotrimazole				
(J01BA01)	0.003076	0.002752	0.005828	-10.5
Clindamycin (J01FF01)	0.00078	0.002762	0.003542	254.1
Spectinomycin (J01XX04)	0.001507	0.00086	0.002367	-42.9
Cefepime (J01DE01)	0.001017	0.000937	0.001954	-7.9
Flucloxacillin (J01CF05)	0.001857		0.001857	-100.0
Vancomycin (J01XA01)	0.000392	0.001189	0.001581	203.3
Cefoperazone + combinations (J01DD62)	0.000996	0.000461	0.001457	-53.7
Cefoperazone + Sulbactam (J01DD62)	0.000497	0.000615	0.001112	23.7
Bacitracin + Neomycin + Polymyxin B		0.00000	***************************************	
(J01XX10)	0.000561	0.000423	0.000984	-24.6
Cefpirome (J01DE02)		0.000867	0.000867	NA
Cilastatin + Imipenem (J01DH51)	0.0003	0.000487	0.000787	62.3
Cloxacillin (J01CF02)		0.000709	0.000709	NA
Amikacin (J01GB06)	0.00027	0.000181	0.000451	-33.0
Cefazolin (J01DB04)	0.000174	0.000275	0.000449	58.0
001DD01)	0.00017	0.000273	0.000117	20.0

Tylosin Tartrate + Doxycycline Hyclate				
(J01AA02)		0.000389	0.000389	NA
PolyMyxin B (J01XB02)	0.000199	0.0001	0.000299	-49.7
Neomycin (J01GB05)		0.000267	0.000267	NA
Roxithromycin (J01FA06)	0.000199		0.000199	-100.0
Sulfadiazine + Trimethoprim (J01EE02)	0.000051	0.000136	0.000187	166.7
Kanamycin (J01GB04)	0.000153		0.000153	-100.0
Sulfadimidine (J01EB03)		0.000123	0.000123	NA
Trimethoprim (J01EA01)	0.00007	0.000035	0.000105	-50.0
Cefaclor (J01DC04)	0.000077	0.000027	0.000104	-64.9
Imipenem + enzyme inhibitor (J01DH56)	0.000089		0.000089	-100.0
Ceftazidime (J01DD02)	0.000056	0.000024	0.00008	-57.1
Linezolid (J01XX08)	0.00007		0.00007	-100.0
Tobramycin (J01GB01)	0.000001	0.000002	0.000003	100.0
Isoniazid + Pyridoxine + Sulfamethoxazole +				
Trimethoprim (J04AM08)		0.000001	0.000001	NA
Ampicillin + Sulbactam (J01CR01)	0		0	NA
Azithromycin + fluconazole + secnidazole				
(J01RA07)		0	0	NA
Erythromycin + combinations (J01FA01)		0	0	N.A.
Period Total	52.934564	64.087946	117.02251	21.1

### Supplementary Table 3: Consumption aggregated at ATC level 3 in the pre-COVID-19 and

### post-COVID-19 era in Tanzania

520

521

522

ATC level 3 Description (Code)	Pre COVID	Post COVID	Class Total	Change %
Sulfonamides And Trimethoprim (J01E)	21.902181	24.134508	46.036689	10.19226
Beta-Lactam Antibacterials, Penicillins (J01C)	17.519188	22.481199	40.000387	28.32329
Quinolone Antibacterials (J01M)	4.344915	4.624895	8.96981	6.443854
Other Antibacterials (J01X)	3.886463	4.615939	8.502402	18.76966
Macrolides, Lincosamides And Streptogramins				
(J01F)	2.38482	5.02076	7.40558	110.5299
Other Beta-Lactam Antibacterials (J01D)	2.119506	2.156056	4.275562	1.724458
Aminoglycoside Antibacterials (J01G)	0.198701	0.569163	0.767864	186.4419
Tetracyclines (J01A)	0.145005	0.250806	0.395811	72.96369
Combinations Of Antibacterials (J01R)	0.219978	0.157205	0.377183	-28.536
Amphenicols (J01B)	0.213806	0.077416	0.291222	-63.7915
Period Total	52.934563	64.087947	117.02251	21.07014

### Supplementary Table 4: Consumption aggregated at ATC level 3 from 2018 to 2021 in

### Tanzania

524

525

526

527

					Four Years
ATC Class level 3	2018	2019	2020	2021	Total
Sulfonamides And Trimethoprim					
(J01E)	14.617083	7.285097	12.50324	11.631268	46.036688
Beta-Lactam Antibacterials,					
Penicillins (J01C)	10.173568	7.34562	11.12656	11.35464	40.000388
Quinolone Antibacterials (J01M)	1.462383	2.882532	2.309063	2.315832	8.96981
Other Antibacterials (J01X)	1.784649	2.101814	1.960377	2.655562	8.502402
Macrolides, Lincosamides And					
Streptogramins (J01F)	1.064215	1.320605	1.65612	3.364641	7.405581
Other Beta-Lactam Antibacterials					
(J01D)	0.872695	1.24681	1.157145	0.998911	4.275561
Aminoglycoside Antibacterials					
(J01G)	0.155795	0.042906	0.07892	0.490243	0.767864
Tetracyclines (J01A)	0.042675	0.10233	0.10106	0.149746	0.395811
Combinations Of Antibacterials					
(J01R)	0.060057	0.159921	0.024369	0.132836	0.377183
Amphenicols (J01B)	0.165188	0.048619	0.051204	0.026212	0.291223
Drugs For Treatment Of					
Tuberculosis (J04A)				0.000001	0.000001
Year Total	30.398308	22.536254	30.968058	33.119892	117.022512

### Supplementary Table 5: Consumption aggregated at ATC level 4 from 2018 to 2021 in

### 531 Tanzania.

528

529

					Four years
ATC Class level 4	2018	2019	2020	2021	Total
Amphenicols (J01BA)	0.165188	0.048619	0.051204	0.026212	0.291223
Beta-Lactamase Resistant Penicillins (J01CF)	0.000632	0.001225	0.000709		0.002566
Beta-Lactamase Sensitive Penicillins (J01CE)	0.97563	0.863383	1.066293	1.04669	3.951996
Carbapenems (J01DH)	0.006551	0.001447	0.00222	0.008116	0.018334

Combinations Of Antibacterials (J01RA)	0.060057	0.159921	0.024369	0.132836	0.377183
Combinations Of Drugs For Treatment Of Tuberculosis (J04AM)				0.000001	0.000001
Combinations Of Penicillins, Incl. Beta-				0.000001	0.000001
Lactamase Inhibitors (J01CR)	3.626861	2.345343	3.431805	4.122006	13.526015
Combinations Of Sulphonamides And					
Trimethoprim Incl. Derivatives (J01EE)	14.617026	7.285085	12.503105	11.631245	46.036461
First Generation Cephalosporins (J01DB)	0.310298	0.687607	0.376731	0.312137	1.686773
Fluoroquinolones (J01MA)	1.454226	2.882532	2.309063	2.315832	8.961653
Fourth Generation Cephalosporins (J01DE)	0.000656	0.000361	0.00063	0.001174	0.002821
Glycopeptide Antibacterials (J01XA)	0.000293	0.000098	0.000166	0.001022	0.001579
Imidazole Derivatives (J01XD)	1.710669	1.952389	1.893326	2.567989	8.124373
Lincosamides (J01FF)	0.000276	0.000503	0.000896	0.001866	0.003541
Macrolides (J01FA)	1.063939	1.320101	1.655224	3.362775	7.402039
Other Aminoglycosides (J01GB)	0.155795	0.042906	0.07892	0.490243	0.767864
Other Antibacterials (J01XX)	0.001017	0.001122	0	0.001283	0.003422
Other Quinolones (J01MB)	0.008157				0.008157
Penicillins With Extended Spectrum (J01CA)	5.570445	4.135668	6.627752	6.185944	22.519809
Second Generation Cephalosporins (J01DC)	0.042137	0.031622	0.009737	0.03655	0.120046
Short-Acting Sulfonamides (J01EB)			0.000123		0.000123
Tetracyclines (J01AA)	0.042675	0.10233	0.10106	0.149746	0.395811
Third Generation Cephalosporins (J01DD)	0.513052	0.525773	0.767827	0.640932	2.447584
(Not classified)	0.072727	0.148216	0.066897	0.085291	0.373131
Year Total	30.398307	22.536251	30.968057	33.11989	117.022505

# Supplementary Table 6: Top (local) importers of antibiotics utilised in Tanzania between 2018 and 2021, with the proportion of each importer in DID in four years and the cumulative contribution for each local importer.

532

533

534

							Cumulative %
Importer	2018	2019	2020	2021	Total	Proportion	contribution
Medical Stores							
Department	12.832301	4.068537	2.884632	3.929656	23.715126	20.26544022	20.2654402
Importer 2	3.61511	3.910759	8.653665	5.725965	21.905499	18.71904794	38.9844882
Importer 3	3.08651	2.834042	5.760543	3.326914	15.008009	12.82489114	51.8093793
Importer 4	1.490486	2.196296	2.374687	3.217808	9.279277	7.929480676	59.73886
Importer 5			0.880014	5.746847	6.626861	5.662894452	65.4017544
Importer 6	1.105711	0.629544	1.501565	1.104843	4.341663	3.710109404	69.1118638
Importer 7	2.82273	0.603366	0.374427	0.270447	4.07097	3.478792362	72.5906562
Importer 8		1.462745	1.136031	1.264955	3.863731	3.301699077	75.8923553
Importer 9	0.130747	1.015805	0.541305	1.593834	3.281691	2.804324666	78.6966799

Importer 10	0.438368	0.577306	0.945605	0.792103	2.753382	2.352865354	81.0495453
Importer 11	0.948832	0.737385	0.49991	0.553922	2.740049	2.341471819	83.3910171
Importer 12	0.357483	0.482545	0.94044	0.807016	2.587484	2.211099462	85.6021166
Importer 13	0.314455	0.718956	1.039605	0.300066	2.373082	2.027885132	87.6300017
Importer 14	0.186325	0.427968	0.267492	0.554332	1.436117	1.227214362	88.8572161
Importer 15	0.164737	0.143458	0.482578	0.611514	1.402287	1.198305393	90.0555215

Supplementary Table 7: Top fifteen (foreign) suppliers of antibiotics utilised in Tanzania between 2018 and 2021, with the proportion of each supplier in DID in four years and the cumulative contribution for each company.

Suppliers	2018	2019	2020	2021	Total	Proportion of total DDI (%)	Cumulative % contribution
Supplier 1, China	11.98331	3.45388	1.077391	0.292197	16.80677	14.36	14.36
Supplier 2, India	2.731248	1.581349	2.996334	1.57263	8.881561	7.59	21.95
Supplier 3, Kenya	0.193801	1.371094	0.696028	5.364539	7.625462	6.52	28.47
Supplier 4, Kenya	0.160403	3.281153	2.964335	3.578167	9.984058	8.53	37.00
Supplier 5, Kenya	0.915313	1.474415	2.85964	1.344799	6.594167	5.63	42.63
Supplier 6, India	0.185795	1.311286	1.165614	3.017761	5.680456	4.85	47.49
Supplier 7, India	0.571838	0.359887	2.322161	1.172949	4.426835	3.78	51.27
Supplier 8, India	0.358325	0.462936	1.478326	2.053054	4.352641	3.72	54.99
Supplier 9, Kenya	3.539278	0.218147	0.358759	0.063429	4.179613	3.57	58.56
Supplier 10, India	0.607576	0.62307	0.77138	1.735099	3.737125	3.19	61.76
Supplier 11, India	0.619548	0.425639	1.864228		2.909415	2.49	64.24
Supplier 12, India	0.760897	0.729129	0.559022	0.656169	2.705217	2.31	66.55
Supplier 13, India		0.83642	0.705891	1.047714	2.590025	2.21	68.77
Supplier 14, India	0.383732	0.805343	0.555065	0.608778	2.352918	2.01	70.78

### Supplementary Table 8: Predicted Defined Dose per 1000 inhabitants per day (DID) from 2022 through 2027 from autoregressive integrated moving average ARIMA (0, 1, 0) model

Year	Actual Daily Defined Dose per 1000 inhabitants per day (DID)	Predicted DID	Lower Control Limit (LCL) of DID	Upper Control Limit (UCL) DID
2018	30.398308			
2019	22.536254	31.305503	-4.05338	66.66438
2020	30.968058	23.443449	-11.9154	58.80233
2021	33.119892	31.875253	-3.48363	67.23413
2022		34.027087	-1.33179	69.38597
2023		34.934281	-15.0707	84.93929
2024		35.841476	-25.4019	97.08485
2025		36.748671	-33.9691	107.4664
2026		37.655865	-41.409	116.7207
2027		38.56306	-48.0482	125.1743